Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

726 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration. Egger M, et al. Among authors: costagliola d, d arminio monforte a. Lancet. 2002 Jul 13;360(9327):119-29. doi: 10.1016/s0140-6736(02)09411-4. Lancet. 2002. PMID: 12126821
Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups.
Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M. Phillips AN, et al. Among authors: costagliola d. AIDS. 1999 Oct 22;13(15):2075-82. doi: 10.1097/00002030-199910220-00010. AIDS. 1999. PMID: 10546860
Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
Salmon-Céron D, Mazeron MC, Chaput S, Boukli N, Senechal B, Houhou N, Katlama C, Matheron S, Fillet AM, Gozlan J, Leport C, Jeantils V, Freymuth F, Costagliola D. Salmon-Céron D, et al. Among authors: costagliola d. AIDS. 2000 May 26;14(8):1041-9. doi: 10.1097/00002030-200005260-00017. AIDS. 2000. PMID: 10853987 Clinical Trial.
Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study.
Descamps D, Calvez V, Izopet J, Buffet-Janvresse C, Schmuck A, Colson P, Ruffault A, Maillard A, Masquelier B, Cottalorda J, Harzic M, Brun-Vézinet F, Costagliola D; ANRS Antiretroviral Resistance Study Group. Descamps D, et al. Among authors: costagliola d. AIDS. 2001 Sep 28;15(14):1777-82. doi: 10.1097/00002030-200109280-00005. AIDS. 2001. PMID: 11579238
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.
Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F, Girard PM; Narval Trial Group. Meynard JL, et al. Among authors: costagliola d. AIDS. 2002 Mar 29;16(5):727-36. doi: 10.1097/00002030-200203290-00008. AIDS. 2002. PMID: 11964529 Clinical Trial.
Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082.
Katlama C, Carcelain G, Duvivier C, Chouquet C, Tubiana R, De Sa M, Zagury L, Calvez V, Autran B, Costagliola D; ILSTIM. Katlama C, et al. Among authors: costagliola d. AIDS. 2002 Oct 18;16(15):2027-34. doi: 10.1097/00002030-200210180-00007. AIDS. 2002. PMID: 12370501 Clinical Trial.
726 results